Multiple Infliximab Biosimilar Switches: Results Following A Nationwide Switch From Originator Infliximab To Biosimilar Ct-P13, And Subsequently To Biosimilar Gp1111, In Real-World Patients With Inflammatory Arthritis Followed In The Danish Danbio Registry

H. Nabi, B. Glintborg,A. G. Loft,O. Hendricks,J. K. Pedersen,S. A. Just,R. Ahmed, K. Danebod,H. L. Munk, A. Colic, A. Linauskas, D. V. Jensen, L. B. Christensen, N. Manilo, N. Lomborg,S. Kristensen,F. Mehnert,N. S. Krogh,M. L. Hetland

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY(2021)

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要